• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alkermes plc

    4/7/25 4:52:09 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    DEFA14A 1 defa14a_2025_notice.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No. )

     

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant o

    Check the appropriate box:

    o

    Preliminary Proxy Statement

    o

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    o

    Definitive Proxy Statement

    x

    Definitive Additional Materials

    o

    Soliciting Material under §240.14a-12

    ALKERMES PLC

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    x

    No fee required.

    o

    Fee paid previously with preliminary materials.

    o

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


     

    img194099001_0.jpg

     

    Alkermes C/O BETANXT, INC. P.O. BOX 8016, CARY, NC 27512-9903 Your vote mattersl Alkermes plc 2025 Annual General Meeting of Shareholders Wednesday, May 21, 2025 1:00 PM, Irish Standard Time Alkermes plc offices, located at Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6 Meeting Materials: Notice of Meeting and Proxy Statement; Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held on May 21, 2025 for Shareholders as of March 14, 2025 To request paper materials, please use one of the following methods: ... For a convenient way to view Alkermes plc's proxy materials, and VOTE your shares, please visit www.proxydocs.com/ALKS. To vote while visiting this site, you will need the 12 digit control number in the box below. You may vote your proxy by Internet or telephone prior to 11:59 PM Eastern Standard Time on May 20, 2025 (4:59 AM Irish Standard Time on May 21, 2025). This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this Notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under U.S. Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper copy. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper copy in time for the Alkermes plc (the "Company") 2025 annual general meeting of shareholders (the "Annual Meeting"), you must make this request on or before May 9, 2025. Internet: www.investorelections.com/ALKS Call: 1-866-648-8133 Email: [email protected] * If requesting receipt of proxy materials, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting proxy materials. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR PROXY PROPOSALS Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img194099001_1.jpg

     

    Alkermes Alkermes plc 2025 Annual General Meeting of Shareholders THE BOARD OF DIRECTORS OF THE COMPANY (THE "BOARD") RECOMMENDS A VOTE: FOR ALL DIRECTOR NOMINEES NAMED IN PROPOSAL 1 FOR PROPOSALS 2, 3, 4, 5 AND 6 1. PROPOSAL To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: 1.01 Shane M. Cooke 1.02 Richard B. Gaynor, M.D. 1.03 Cato T. Laurencin, M.D., Ph.D. 1.04 Nancy S. Lurker 1.05 Brian P. McKeon 1.06 Richard F. Pops 1.07 Nancy L. Snyderman, M.D. 1.08 Frank Anders Wilson 1.09 Christopher I. Wright, M.D., Ph.D. 2. To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. 3. To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration. To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. 4. 5. To renew Board authority to allot and issue shares under Irish law. 6. To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law. If any other matter is presented at the Annual Meeting upon which a vote may be properly taken, ordinary shares represented by all proxy cards received by the Company will be voted at the discretion of the named proxy holders as set forth on the proxy card. Any shareholder entitled to attend, speak and vote at the Annual Meeting may appoint one or more proxies, who need not be a shareholder of record of the Company. If you wish to appoint as proxy any person other than the individuals specified on the Company's proxy card, you may do so by contacting the Company Secretary at Alkermes plc, Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6, Attention: Company Secretary, or by delivering to the Company Secretary a proxy card in the form mailed to you or in the form set forth in Section 184 of the Irish Companies Act 2014. To obtain directions to attend the Annual Meeting, please contact the Company's Investor Relations team at [email protected]. The Company's Irish statutory financial statements for the year ended December 31, 2024, including the reports of the directors and auditors thereon, are available on the Annual Reports page of the Investors section of the Company's website at http://investor.alkermes.com. If you wish to receive a paper or e-mail copy, please contact the Company Secretary using the contact information above.


    Get the next $ALKS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    3/19/2024$37.00Outperform
    Robert W. Baird
    2/20/2024$25.00Neutral → Sell
    UBS
    11/20/2023$33.00Neutral
    JP Morgan
    More analyst ratings

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alkermes plc

      SC 13G - Alkermes plc. (0001520262) (Subject)

      11/14/24 1:22:34 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/12/24 1:28:21 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/8/24 10:46:38 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Alkermes plc

      SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)

      5/13/25 10:23:10 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Alkermes plc

      DEFA14A - Alkermes plc. (0001520262) (Filer)

      5/12/25 5:03:55 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Alkermes plc

      10-Q - Alkermes plc. (0001520262) (Filer)

      5/1/25 4:05:29 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Financials

    Live finance-specific insights

    See more
    • Alkermes plc Reports First Quarter 2025 Financial Results

      —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev

      5/1/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Report First Quarter Financial Results on May 1, 2025

      DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc  Alkermes plc is a global biopharmaceutic

      4/17/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

      —    Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — —    GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — —    ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN, Feb. 12, 2025  /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company.

      2/12/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alkermes plc Reports First Quarter 2025 Financial Results

      —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev

      5/1/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Report First Quarter Financial Results on May 1, 2025

      DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc  Alkermes plc is a global biopharmaceutic

      4/17/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

      DUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioi

      4/2/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

      DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

      3/7/24 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/1/23 6:16:00 PM ET
      $ALK
      $ALKS
      $AWI
      $BLDR
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

      —  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.  "Dr. Loew's deep knowledge of the oncology fi

      6/1/23 4:01:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lurker Nancy covered exercise/tax liability with 1,459 units of Ordinary Shares and converted options into 6,075 units of Ordinary Shares (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      4/14/25 5:17:43 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Finance (Interim PAO) Parisi Samuel Joseph converted options into 2,746 units of Ordinary Shares, covered exercise/tax liability with 808 units of Ordinary Shares and sold $65,892 worth of Ordinary Shares (1,938 units at $34.00) (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      2/28/25 5:19:13 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Commercial Officer Nichols Christian Todd converted options into 5,409 units of Ordinary Shares and covered exercise/tax liability with 2,402 units of Ordinary Shares, increasing direct ownership by 3% to 92,875 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      2/28/25 5:18:13 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target

      RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00

      3/13/25 7:24:22 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Plc upgraded by UBS with a new price target

      UBS upgraded Alkermes Plc from Sell to Neutral and set a new price target of $38.00 from $21.00 previously

      3/4/25 8:28:23 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Alkermes Plc with a new price target

      Deutsche Bank initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $40.00

      2/11/25 7:00:38 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care